Specialty Pharmacy

Phase 3 study results showed that the new HIV therapy ibalizumab reduced viral replication and increased immunity in drug-resistant patients.

Top news of the day from across the health care landscape

Machine-learning technique reduces toxic treatment dosing for glioblastoma while maintaining tumor-shrinking benefits.

The FDA approved cenegermin (Oxervate), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea.

Nanoparticles that act as an ‘on and off’ switch could help improve the safety and efficacy of CAR T-cell therapy.

More than 4 in 10 women with asthma may develop chronic obstructive pulmonary disorder, but many risk factors are modifiable.

Top news of the day from across the health care landscape

The latest recommendation from the United States Preventive Services Task Force (USPSTF) states that women aged 30 years or older have a new option.

A recent study finds patients who experience frequent basal cell carcinomas are 3 times more likely to develop other cancers.

Pembrolizumab in combination with chemotherapy reduced the risk of death by half in patients with metastatic, non-squamous non-small cell lung cancer compared with chemotherapy alone.

An expert panel of health care providers and patients are recommending that opioid prescribing limits should be based on the operation performed rather than a blanket approach.

Understanding specialty drug pricing, and the flow of health care dollars through the lens of the stakeholders involved.

Interventions must address HIV testing and beliefs among both patients and providers in order to reach underserved populations.

The use of benzodiazepines and related z-drugs was found to be associated with a modest increase in the risk of Alzheimer disease in a case-control trial.

Top news of the day from across the health care landscape.

Study evaluates the effect of multiple sclerosis treatment alemtuzumab (Lemtrada) on the B-cell component of MS.

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses biosimilars and the potential impact on patient care.

New study finds that privately-insured patients with follicular lymphoma have better survival outcomes.

Testing individuals not considered high-risk for hepatitis C virus addresses increase in new infections associated with opioid epidemic.

Celtaxsys’ acebilustat is the first novel anti-inflammatory molecule with the potential to both reduce pulmonary exacerbations and prolong time to first exacerbation.

The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients.

Top news of the day from across the health care landscape.

With this approval, nivolumab (Opdivo) offers a new treatment option for patients with small cell lung cancer whose cancer has progressed after 2 or more prior lines of therapy.

Two new studies highlight trends in life expectancy and mortality across high-income countries, citing worsening health in the United States.

Assessment of neurofilament light chain levels offers real-time, efficient measure marker of multiple sclerosis progression.

States that chose to expand Medicaid eligibility under the Affordable Care Act (ACA) have seen a greater decrease in uninsured rates among low-income patients.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.